Sindusfarma Monthly Prescription (Aug.23): Gradually Evolving

Sindusfarma data from Aug.23 showed a continued improvement on sales trends, with sell-in sales growth reaching 12% y/y (or 15% y/y LTM), mainly driven by higher price (+9% y/y), albeit also with improving volume trends, with (+3% y/y) after two months of decrease/stability of volumes (-3% in June and flat in July). Generics sell-in sales also accelerated slightly to 20% y/y (or 15% y/y LTM) when compared to Jul.23 (19% y/y and 14% y/y LTM), also driven by higher prices (11% y/y). Moreover, sell-out sales (i.e., using PMB as a proxy) continued to evolve and reached +10% y/y in Aug.23 (vs. +8% y/y in July.23). Sales trends continue to gradually evolve, likely driven by easier volume comps (e.g., as high volume comps from 2022 flu season), although we note that sell-out growth continues in the single-digit range, which naturally remains an area of attention going forward.

Veja mais